Li Yuan-Bin, Lin Li-Zhu, Guan Jie-Shan, Chen Chang-Ming, Zuo Qian, Lin Bao-Qi
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Sep;36(9):1076-1081.
Objective To preliminarily observe miRNA gene profiles in benefit serum of advanced non-small cell lung cancer (NSCLC) treated by TCM combined Western medicine (WM) , and to seek for molecular markers for its efficacy monitoring and prediction. Methods Recruited were 5 advanced NSCLC patients who received TCM combined WM treatment and obtained efficacy benefit ( as the treatment group) , 3 advanced NSCLC patients who received early treatment ( as the lung cancer group) , and 3 healthy subjects (as the control group). Serum samples were collected and total RNA was extracted using Trizol method. Using microRNA PCR ARRAY chip technology (product of Exiqon Company) , differentially miRNA expression profiling in serum between the lung cancer group and the control group, and between the treatment group and the lung cancer group were detected. Benefit miRNA expression profiling was ob- tained based on cluster analysis and comparative analysis. Results After tested by miRNA PCR ARRAY and managed by data analysis, a total of 42 miRNAs with more than 2 folds difference were screened in the lung cancer group and the control group, including 29 up-regulated and 12 down-regulated miRNAs. Be- sides, miR-10b-5p, miR-21-5p, miR-182-5p, miR-361-3p, and miR-382-5p were statistically different (P < 0. 05). A total of 45 miRNAs with more than 2 folds difference were screened in the treatment group and the lung cancer group, including 12 up-regulated and 33 down-regulated miRNAs. Fifteen miRNAs were statistically different including miR-137-3p, miR-182-5p, miR-376a-3p, miR-382-5p, miR-409-3p, miR-10a-5p, miR-21-5p, miR-29a-3p, miR-141-3p, miR-150-5p, miR-200c-3p, miR-342-3p, miR-365a-3p, miR-375, miR- 502-3p (P<0.05). Totally 22 miRNAs were screened in the treatment group with more than 2 folds differ- ence as compared with the lung cancer group and with less than or equivalent to 2 folds difference as com- pared with the control group, including 7 up-regulated and 15 down-regulated miRNAs, of which, miR-127- 3p, miR-182-5p, miR-382-5p, miR-409-3p, miR-10a-5p, miR-21-5p, miR-141-3p, miR-342-3p were statistically different (P <0. 05). Conclusion miRNAs including miR-21-5p, miR-182-5p, miR-382-5p are promising to become molecular markers for efficacy monitoring and prediction of advanced NSCLC treated by TCM combined WM, which provides reference for individualized treating advanced NSCLC.
目的 初步观察中西医结合治疗晚期非小细胞肺癌（NSCLC）疗效较好患者血清中的miRNA基因谱，寻找其疗效监测及预测的分子标志物。方法 选取5例接受中西医结合治疗且疗效较好的晚期NSCLC患者（作为治疗组），3例接受早期治疗的晚期NSCLC患者（作为肺癌组），3例健康受试者（作为对照组）。采集血清样本，采用Trizol法提取总RNA。利用microRNA PCR ARRAY芯片技术（Exiqon公司产品），检测肺癌组与对照组、治疗组与肺癌组血清中miRNA的差异表达谱。通过聚类分析和比较分析获得有益的miRNA表达谱。结果 经miRNA PCR ARRAY检测及数据分析，肺癌组与对照组共筛选出42个差异倍数大于2倍的miRNA，其中上调29个，下调12个。此外，miR-10b-5p、miR-21-5p、miR-182-5p、miR-361-3p和miR-382-5p差异有统计学意义（P<0.05）。治疗组与肺癌组共筛选出45个差异倍数大于2倍的miRNA，其中上调12个，下调33个。15个miRNA差异有统计学意义，包括miR-137-3p、miR-182-5p、miR-376a-3p、miR-382-5p、miR-409-3p、miR-10a-5p、miR-21-5p、miR-29a-3p、miR-141-3p、miR-150-5p、miR-200c-3p、miR-342-3p、miR-365a-3p、miR-375、miR-502-3p（P<0.05）。治疗组与肺癌组相比差异倍数大于2倍且与对照组相比差异倍数小于或等于2倍的miRNA共筛选出22个，其中上调7个，下调15个，其中miR-127-3p、miR-182-5p、miR-382-5p、miR-409-3p、miR-10a-5p、miR-21-5p、miR-141-3p、miR-342-3p差异有统计学意义（P<0.05）。结论 miR-21-5p、miR-182-5p、miR-382-5p等miRNA有望成为中西医结合治疗晚期NSCLC疗效监测及预测的分子标志物，为晚期NSCLC个体化治疗提供参考。
